Biomarin Pharmaceutical (BMRN) Shares Outstanding (Diluted Average) (2009 - 2026)

Biomarin Pharmaceutical has disclosed Shares Outstanding (Diluted Average) across 13 years of filings, most recently posting $197.7 million for Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 0.61% year-over-year to $197.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.7 million (up 0.61% YoY) and the FY2025 annual result came in at $197.4 million, changed 0.35% from the prior year.
• Shares Outstanding (Diluted Average) held at $197.7 million in Q1 2026, from $197.4 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $200.5 million in Q2 2024 and troughed at $189.0 million in Q4 2022.
• A 5-year average of $195.1 million and a median of $195.0 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) grew 5.71% — and 2025, when it dropped 2.36%.
• Tracing BMRN's Shares Outstanding (Diluted Average) over 5 years: stood at $189.0 million in 2022, then increased by 1.39% to $191.6 million in 2023, then advanced by 2.67% to $196.7 million in 2024, then advanced by 0.35% to $197.4 million in 2025, then advanced by 0.14% to $197.7 million in 2026.
• Business Quant data shows BMRN's Shares Outstanding (Diluted Average) at $197.7 million in Q1 2026, $197.4 million in Q4 2025, and $192.0 million in Q3 2025.